CELESTONE by Merck & Co. is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus. First approved in 1964.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
CELESTONE (betamethasone) is a synthetic glucocorticoid oral syrup approved in 1964 for treatment of systemic inflammatory and autoimmune conditions. It treats dermatomyositis, polymyositis, and systemic lupus erythematosus by suppressing immune response and reducing inflammation through enhanced anti-inflammatory action via a 16β-methyl group modification. The drug is readily absorbed from the gastrointestinal tract and provides sustained anti-inflammatory effects with reduced mineralocorticoid activity compared to natural glucocorticoids.
This legacy product faces LOE pressures with minimal modern support; brand teams managing CELESTONE likely operate in maintenance mode with flat or declining headcount.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Worked on CELESTONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CELESTONE offers minimal career development opportunity due to its mature lifecycle and approaching loss of exclusivity; roles are primarily maintenance-focused on legacy product stewardship rather than growth initiatives. Professionals assigned to this product should seek concurrent exposure to newer pipeline assets or consider lateral moves to higher-growth therapeutic areas.